Zimbabwe has rejected a major American health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's request for sensitive data.
This move came to light following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
A government representative later explained that the US was seeking biological samples for research and commercial purposes while was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for continued talks to secure a agreement suitable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a comparable situation in Kenya, where a high court blocked a similar deal with the US after concerns were filed about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost openness and accountability.
Based on reports, Sixteen nations in Africa have to date agreed to similar health pacts, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our citizens should a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks previously established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that honours the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but recommended that talks should continue given that much of the nation's HIV programmes were funded by international support.
"Where specific concerns arise, such as those relating to data governance or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the continuing debate between accepting much-needed international aid and safeguarding local interests in an increasingly data-driven world.